欧洲膀胱过度活动症治疗市场预测至 2028 年 – COVID-19 影响和区域分析 – 按药物疗法（抗胆碱能药物、米拉贝隆、肉毒杆菌、神经刺激和膀胱内滴注）和疾病类型（特发性膀胱过度活动症和神经源性膀胱）
No. of Pages: 153 | Report Code: BMIRE00027805 | Category: Life Sciences
No. of Pages: 153 | Report Code: BMIRE00027805 | Category: Life Sciences
尿路感染（UTI）可能会导致膀胱壁肌肉活动增加，导致类似于膀胱过度活动症的症状。引起尿路感染的细菌存在于尿路上皮细胞内壁，当先天免疫力低下时，它们会攻击宿主身体。患有复发性尿路感染的个体被发现存在排尿功能障碍和逼尿肌过度活动，这些功能异常会进一步损害尿路上皮屏障的完整性。尿路感染分别是该国门诊就诊和急诊就诊的第八和第五常见原因。此外，根据国家健康与护理卓越研究所的数据，尿路感染是英国最常见的医院获得性感染之一，约占所有感染的 23%。根据 BMC Family Practice 的数据，2019 年荷兰泌尿道感染咨询占急诊就诊人数的 2% 左右。同样，在法国，每年约有 4—60 万人患有泌尿道感染。因此，尿路感染发病率的增加，加上尿路感染与膀胱过度活动症的关联，是促进欧洲膀胱过度活动症治疗市场增长的重要因素之一。
欧洲膀胱过度活动症治疗市场分为德国、英国、法国、意大利、西班牙和欧洲其他地区。欧洲在全球膀胱过度活动症治疗市场中占据重要地位，预计在预测期内将出现可观的复合年增长率。由于老年人口的存在，对膀胱过度活动症治疗的需求不断增长，正在推动欧洲市场的增长。此外，阻碍尿路功能的神经系统疾病和糖尿病的流行可能为未来几年膀胱过度活动症治疗的增长创造机会。英国议会数据显示，2019年英国总人口中约五分之一年龄在65岁及以上。此外，2009年至2019年该年龄段人口数量增加了23%，而英国总人口同期仅增长7%。英国糖尿病协会表示，2019 年约有 390 万人被诊断患有糖尿病，2021 年这一数字将达到 470 万人。英国糖尿病患病率的上升和老年人口的增加导致膀胱过度活动症病例激增，从而刺激了对糖尿病的需求。
欧洲膀胱过度活动症治疗市场根据药物治疗、疾病类型和国家进行细分。
欧洲膀胱过度活动症治疗市场根据药物治疗、疾病类型和国家进行细分。
AbbVie Inc; Alembic 制药有限公司；安斯泰来制药公司；远藤制药公司；久光制药有限公司；美敦力公司；辉瑞公司；和 Teva Pharmaceutical Industries Ltd 是欧洲膀胱过度活动症治疗市场的领先公司。
Strategic insights for Europe Overactive Bladder Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 1,111.05 Million |
| Market Size by 2028 | US$ 1,318.55 Million |
| Global CAGR (2022 - 2028) | 2.9% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By 药物治疗
|
| Regions and Countries Covered | 欧洲
|
| Market leaders and key company profiles |
The regional scope of Europe Overactive Bladder Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Europe Overactive Bladder Treatment Market is valued at US$ 1,111.05 Million in 2022, it is projected to reach US$ 1,318.55 Million by 2028.
As per our report Europe Overactive Bladder Treatment Market, the market size is valued at US$ 1,111.05 Million in 2022, projecting it to reach US$ 1,318.55 Million by 2028. This translates to a CAGR of approximately 2.9% during the forecast period.
The Europe Overactive Bladder Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Overactive Bladder Treatment Market report:
The Europe Overactive Bladder Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Overactive Bladder Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Overactive Bladder Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Overactive Bladder Treatment Market
